Immune Checkpoint Inhibitors Market Synopsis:
Immune Checkpoint Inhibitors Market Size Was Valued at USD 48.51 Billion in 2023, and is Projected to Reach USD 201.15 Billion by 2032, Growing at a CAGR of 17.12% From 2024-2032.
The immune checkpoint inhibitors market has been experiencing significant growth in the last couple of years due to the growing rate of different types of cancer and a deeper insight into the immune system in cancer treatment. Immune checkpoint inhibitor drugs are a relatively new set of drugs that work to renew the immune system’s ability to identify cancer cells through hindering proteins that have a restraining effect on the immune system including CTLA-4, PD-1 and PD-L1. This concept has transformed the cancer therapy practice as now its patients types like melanoma, lung, bladder etc which were previously uploaded as untreatable have now treatment propositions.
Immune checkpoint inhibitors with durable responses have been introduced to the market, and there are hundreds of ongoing studies testing immune checkpoint inhibitors singly and in combination with other drugs in various cancers.. Many firms in the market such as Bristol-Myers Squibb, Merck & Co., and Roche have increased their research efforts to develop new products and improve on current medical therapies. Continual use of these therapies in clinical situations, coupled with growing regulatory endorsements, has added to market growth and placed immune checkpoint inhibitors at the forefront of contemporary oncology treatment.• Nevertheless, the immune checkpoint inhibitors market also has its issues: its high cost, development of immune-related adverse events, and the variability of patient’s response to the therapy.s and for various malignancies. Key players in the market, including pharmaceutical giants like Bristol-Myers Squibb, Merck & Co., and Roche, are investing heavily in research and development to expand their product portfolios and enhance the effectiveness of existing treatments. The growing adoption of these therapies in clinical settings, along with increasing approvals from regulatory authorities, has further fueled market expansion, making immune checkpoint inhibitors a cornerstone of modern oncology.
However, the immune checkpoint inhibitors market also faces challenges, including high treatment costs, the occurrence of immune-related adverse events, and variable patient responses to therapy. Moreover, present biomarkers are still rather limited and there is a clear demand for more accurate biomarkers that could guide doctors in developing individual patient’s treatment. Nevertheless, this market has great potential: existing research, new technologies in creating drugs, the possible synergistic action of combinations of drugs associated with lower toxicity should not be discounted. New knowledge about the immune system is added all the time and it is only a matter of time before the immune checkpoint inhibitors market progresses further and boosts cancer patient survival rates around the globe.
Immune Checkpoint Inhibitors Market Trend Analysis:
Increased Combination Therapies
-
Thus, one of the most important market trends is the shift of focus towards combining immune checkpoint inhibitors with other treatments.. Scientists and clinicians are now examining the interaction that may occur when combining immune checkpoint inhibitors with other therapies including chemotherapy, targeted therapy, and other immunotherapies. Its purpose is to increase the therapeutic index and also to gain better results in patient treatment, especially in cases where individual drugs that do not give satisfactory results. Clinical trials are currently being carried out to determine different checkpoints that are being conducted, which can pave way for addition of more checkpoint inhibitors and basically come up with better treatment plans.
Personalized Medicine Approaches
-
One more trend is personalized medicine when the use of immune checkpoint inhibitors is concerned.. As knowledge regarding tumour biology and immunology expands, there is increasing interest in directing biomarkers to deleterious immune checkpoint inhibitors. This makes the therapy to fit every patient hence offering the right treatment to the patient depending on the tumors type and the immune system. It is for these reasons that the genomic and proteomic technologies can improve the accuracy of this treatment and reduce its side effects to improve further the results in cancer treatment.
Immune Checkpoint Inhibitors Market Segment Analysis:
Immune Checkpoint Inhibitors Market Segmented on the basis of Indication, Target, Route of Administration, End-Users, Distribution Channel, and Region
By Indication, Breast Cancer segment is expected to dominate the market during the forecast period
-
Cancer indications are the key attributors to the current immune checkpoint inhibitors market and its expanding sphere of applicability to different tumor variations.. In particular, lung cancer is still the predominant indication; the targets are PD-1 and PD-L1 inhibitors, which have dramatically changed the therapeutic approach for the later stages of the illness. In turn, breast cancer has experienced a rapidly growing trend towards the use of immune checkpoint inhibitors, especially for triple-negative breast cancer, in which these treatments have proven to be effective. Bladder cancer and kidney cancer are two other large segments of the market because checkpoint inhibitors are a new option for people with few treatment alternatives. Other imitations include cervical cancer and Hodgkin lymphoma, which current have research and trial in use to extend the applicability of these new treatments. Lymphomas are particularly prevalent and generic solid tumors are becoming progressively more popular, with current trials performed to check the efficacy of immune checkpoint inhibitors in most types of cancers, thus, stoking the market demand and product differentiation.
Distribution Channel, Hospital Pharmacy segment expected to held the largest share
-
Distribution channel is therefore a significant component in the immune checkpoint inhibitors market, since these innovative types of treatment are vital to patients.. The major distribution channels are hospital pharmacy, community retail pharmacy, and limited distribution circuits. Hospital pharmacies are also engaged because they care for admitted patients, and administer cancer treatments that may have significant side effects, or require close supervision in outpatient facilities where such services are routinely available. Community retail pharmacies also engage in the dispensing of ICI, especially for ambulatory care, thus making such a therapy available to patients after discharge or other patients treated within their neighborhood settings. Also, there is evolution of specialised distribution channels that can address the specific transportation needs of these delivery systems in order to meet compulsory temperature management standards for biologic products. The use of independent agents of distribution in this manner is crucial for the assembling of immune checkpoint inhibitors and their delivery to patients and their integration into the framework of comprehensive cancer treatment.
Immune Checkpoint Inhibitors Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
-
North America is likely to have the largest share in the immune checkpoint inhibitors market during forecast period owing to existence of well established healthcare facilities, high research activity, and reputation of key pharma vendors involved in oncology drugs.. Immune checkpoint inhibitors have also seen a steady rise in uptake over the years due to the success recorded in trials and more especially the rising nod from authorities including the FDA on new therapies. Besides, an increase in the number of cancer patients and increased understanding by medical personnel and patients with immunotherapy also leads to active market development in North America. In addition, the fact that the region continues to embrace personalised medicine as well as new developments in concurrent treatments for the immune checkpoint inhibitors market make the region poised to remain ahead globally.
Active Key Players in the Immune Checkpoint Inhibitors Market:
-
Sanofi (Paris, France)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Merck & Co. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Eli Lilly and Company (U.S.)
- Regeneron Pharmaceuticals Inc. (U.S.)
- AstraZeneca PLC (United Kingdom)
- Shanghai Jhunsi Biosciences Ltd (China)
- Immutep Ltd (Australia)
- BeiGene Ltd (China)
- GlaxoSmithKline PLC (United Kingdom)
- Other Active Players
|
Global Immune Checkpoint Inhibitors Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 48.51 Billion |
|
Forecast Period 2024-32 CAGR: |
17.12% |
Market Size in 2032: |
USD 201.15 Billion |
|
Segments Covered: |
By Indication |
|
|
|
By Target |
|
||
|
By End-Users |
|
||
|
Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Immune Checkpoint Inhibitors Market by Indication
4.1 Immune Checkpoint Inhibitors Market Snapshot and Growth Engine
4.2 Immune Checkpoint Inhibitors Market Overview
4.3 Breast Cancer
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Breast Cancer: Geographic Segmentation Analysis
4.4 Bladder Cancer
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Bladder Cancer: Geographic Segmentation Analysis
4.5 Cervical Cancer
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Cervical Cancer: Geographic Segmentation Analysis
4.6 Hodgkin Lymphoma
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Hodgkin Lymphoma: Geographic Segmentation Analysis
4.7 Liver Cancer
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Liver Cancer: Geographic Segmentation Analysis
4.8 Lung Cancer
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Lung Cancer: Geographic Segmentation Analysis
4.9 Kidney Cancer
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.9.3 Key Market Trends, Growth Factors and Opportunities
4.9.4 Kidney Cancer: Geographic Segmentation Analysis
4.10 Solid Cancer
4.10.1 Introduction and Market Overview
4.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.10.3 Key Market Trends, Growth Factors and Opportunities
4.10.4 Solid Cancer: Geographic Segmentation Analysis
4.11 Others
4.11.1 Introduction and Market Overview
4.11.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.11.3 Key Market Trends, Growth Factors and Opportunities
4.11.4 Others: Geographic Segmentation Analysis
Chapter 5: Immune Checkpoint Inhibitors Market by Target
5.1 Immune Checkpoint Inhibitors Market Snapshot and Growth Engine
5.2 Immune Checkpoint Inhibitors Market Overview
5.3 PD-1
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 PD-1: Geographic Segmentation Analysis
5.4 PD-L1
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 PD-L1: Geographic Segmentation Analysis
5.5 CTLA-4
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 CTLA-4: Geographic Segmentation Analysis
5.6 Others
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Others: Geographic Segmentation Analysis
Chapter 6: Immune Checkpoint Inhibitors Market by Route of Administration
6.1 Immune Checkpoint Inhibitors Market Snapshot and Growth Engine
6.2 Immune Checkpoint Inhibitors Market Overview
6.3 Oral
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Oral: Geographic Segmentation Analysis
6.4 Parenteral
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Parenteral: Geographic Segmentation Analysis
6.5 Others
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Others: Geographic Segmentation Analysis
Chapter 7: Immune Checkpoint Inhibitors Market by End-Users
7.1 Immune Checkpoint Inhibitors Market Snapshot and Growth Engine
7.2 Immune Checkpoint Inhibitors Market Overview
7.3 Hospitals
7.3.1 Introduction and Market Overview
7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.3.3 Key Market Trends, Growth Factors and Opportunities
7.3.4 Hospitals: Geographic Segmentation Analysis
7.4 Specialty Clinics
7.4.1 Introduction and Market Overview
7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.4.3 Key Market Trends, Growth Factors and Opportunities
7.4.4 Specialty Clinics: Geographic Segmentation Analysis
7.5 Others
7.5.1 Introduction and Market Overview
7.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.5.3 Key Market Trends, Growth Factors and Opportunities
7.5.4 Others: Geographic Segmentation Analysis
Chapter 8: Immune Checkpoint Inhibitors Market by Distribution Channel
8.1 Immune Checkpoint Inhibitors Market Snapshot and Growth Engine
8.2 Immune Checkpoint Inhibitors Market Overview
8.3 Hospital Pharmacy
8.3.1 Introduction and Market Overview
8.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
8.3.3 Key Market Trends, Growth Factors and Opportunities
8.3.4 Hospital Pharmacy: Geographic Segmentation Analysis
8.4 Retail Pharmacy
8.4.1 Introduction and Market Overview
8.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
8.4.3 Key Market Trends, Growth Factors and Opportunities
8.4.4 Retail Pharmacy: Geographic Segmentation Analysis
8.5 Others
8.5.1 Introduction and Market Overview
8.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
8.5.3 Key Market Trends, Growth Factors and Opportunities
8.5.4 Others: Geographic Segmentation Analysis
Chapter 9: Company Profiles and Competitive Analysis
9.1 Competitive Landscape
9.1.1 Competitive Benchmarking
9.1.2 Immune Checkpoint Inhibitors Market Share by Manufacturer (2023)
9.1.3 Industry BCG Matrix
9.1.4 Heat Map Analysis
9.1.5 Mergers and Acquisitions
9.2 SANOFI (FRANCE)
9.2.1 Company Overview
9.2.2 Key Executives
9.2.3 Company Snapshot
9.2.4 Role of the Company in the Market
9.2.5 Sustainability and Social Responsibility
9.2.6 Operating Business Segments
9.2.7 Product Portfolio
9.2.8 Business Performance
9.2.9 Key Strategic Moves and Recent Developments
9.2.10 SWOT Analysis
9.3 F. HOFFMANN-LA ROCHE LTD. (SWITZERLAND)
9.4 MERCK & CO. (U.S.)
9.5 BRISTOL-MYERS SQUIBB COMPANY (U.S.)
9.6 ELI LILLY AND COMPANY (U.S.)
9.7 REGENERON PHARMACEUTICALS INC. (U.S.)
9.8 ASTRAZENECA PLC (UNITED KINGDOM)
9.9 SHANGHAI JHUNSI BIOSCIENCES LTD (CHINA)
9.10 IMMUTEP LTD (AUSTRALIA)
9.11 BEIGENE LTD (CHINA)
9.12 GLAXOSMITHKLINE PLC (UNITED KINGDOM)
9.13 OTHER ACTIVE PLAYERS
Chapter 10: Global Immune Checkpoint Inhibitors Market By Region
10.1 Overview
10.2. North America Immune Checkpoint Inhibitors Market
10.2.1 Key Market Trends, Growth Factors and Opportunities
10.2.2 Top Key Companies
10.2.3 Historic and Forecasted Market Size by Segments
10.2.4 Historic and Forecasted Market Size By Indication
10.2.4.1 Breast Cancer
10.2.4.2 Bladder Cancer
10.2.4.3 Cervical Cancer
10.2.4.4 Hodgkin Lymphoma
10.2.4.5 Liver Cancer
10.2.4.6 Lung Cancer
10.2.4.7 Kidney Cancer
10.2.4.8 Solid Cancer
10.2.4.9 Others
10.2.5 Historic and Forecasted Market Size By Target
10.2.5.1 PD-1
10.2.5.2 PD-L1
10.2.5.3 CTLA-4
10.2.5.4 Others
10.2.6 Historic and Forecasted Market Size By Route of Administration
10.2.6.1 Oral
10.2.6.2 Parenteral
10.2.6.3 Others
10.2.7 Historic and Forecasted Market Size By End-Users
10.2.7.1 Hospitals
10.2.7.2 Specialty Clinics
10.2.7.3 Others
10.2.8 Historic and Forecasted Market Size By Distribution Channel
10.2.8.1 Hospital Pharmacy
10.2.8.2 Retail Pharmacy
10.2.8.3 Others
10.2.9 Historic and Forecast Market Size by Country
10.2.9.1 US
10.2.9.2 Canada
10.2.9.3 Mexico
10.3. Eastern Europe Immune Checkpoint Inhibitors Market
10.3.1 Key Market Trends, Growth Factors and Opportunities
10.3.2 Top Key Companies
10.3.3 Historic and Forecasted Market Size by Segments
10.3.4 Historic and Forecasted Market Size By Indication
10.3.4.1 Breast Cancer
10.3.4.2 Bladder Cancer
10.3.4.3 Cervical Cancer
10.3.4.4 Hodgkin Lymphoma
10.3.4.5 Liver Cancer
10.3.4.6 Lung Cancer
10.3.4.7 Kidney Cancer
10.3.4.8 Solid Cancer
10.3.4.9 Others
10.3.5 Historic and Forecasted Market Size By Target
10.3.5.1 PD-1
10.3.5.2 PD-L1
10.3.5.3 CTLA-4
10.3.5.4 Others
10.3.6 Historic and Forecasted Market Size By Route of Administration
10.3.6.1 Oral
10.3.6.2 Parenteral
10.3.6.3 Others
10.3.7 Historic and Forecasted Market Size By End-Users
10.3.7.1 Hospitals
10.3.7.2 Specialty Clinics
10.3.7.3 Others
10.3.8 Historic and Forecasted Market Size By Distribution Channel
10.3.8.1 Hospital Pharmacy
10.3.8.2 Retail Pharmacy
10.3.8.3 Others
10.3.9 Historic and Forecast Market Size by Country
10.3.9.1 Russia
10.3.9.2 Bulgaria
10.3.9.3 The Czech Republic
10.3.9.4 Hungary
10.3.9.5 Poland
10.3.9.6 Romania
10.3.9.7 Rest of Eastern Europe
10.4. Western Europe Immune Checkpoint Inhibitors Market
10.4.1 Key Market Trends, Growth Factors and Opportunities
10.4.2 Top Key Companies
10.4.3 Historic and Forecasted Market Size by Segments
10.4.4 Historic and Forecasted Market Size By Indication
10.4.4.1 Breast Cancer
10.4.4.2 Bladder Cancer
10.4.4.3 Cervical Cancer
10.4.4.4 Hodgkin Lymphoma
10.4.4.5 Liver Cancer
10.4.4.6 Lung Cancer
10.4.4.7 Kidney Cancer
10.4.4.8 Solid Cancer
10.4.4.9 Others
10.4.5 Historic and Forecasted Market Size By Target
10.4.5.1 PD-1
10.4.5.2 PD-L1
10.4.5.3 CTLA-4
10.4.5.4 Others
10.4.6 Historic and Forecasted Market Size By Route of Administration
10.4.6.1 Oral
10.4.6.2 Parenteral
10.4.6.3 Others
10.4.7 Historic and Forecasted Market Size By End-Users
10.4.7.1 Hospitals
10.4.7.2 Specialty Clinics
10.4.7.3 Others
10.4.8 Historic and Forecasted Market Size By Distribution Channel
10.4.8.1 Hospital Pharmacy
10.4.8.2 Retail Pharmacy
10.4.8.3 Others
10.4.9 Historic and Forecast Market Size by Country
10.4.9.1 Germany
10.4.9.2 UK
10.4.9.3 France
10.4.9.4 The Netherlands
10.4.9.5 Italy
10.4.9.6 Spain
10.4.9.7 Rest of Western Europe
10.5. Asia Pacific Immune Checkpoint Inhibitors Market
10.5.1 Key Market Trends, Growth Factors and Opportunities
10.5.2 Top Key Companies
10.5.3 Historic and Forecasted Market Size by Segments
10.5.4 Historic and Forecasted Market Size By Indication
10.5.4.1 Breast Cancer
10.5.4.2 Bladder Cancer
10.5.4.3 Cervical Cancer
10.5.4.4 Hodgkin Lymphoma
10.5.4.5 Liver Cancer
10.5.4.6 Lung Cancer
10.5.4.7 Kidney Cancer
10.5.4.8 Solid Cancer
10.5.4.9 Others
10.5.5 Historic and Forecasted Market Size By Target
10.5.5.1 PD-1
10.5.5.2 PD-L1
10.5.5.3 CTLA-4
10.5.5.4 Others
10.5.6 Historic and Forecasted Market Size By Route of Administration
10.5.6.1 Oral
10.5.6.2 Parenteral
10.5.6.3 Others
10.5.7 Historic and Forecasted Market Size By End-Users
10.5.7.1 Hospitals
10.5.7.2 Specialty Clinics
10.5.7.3 Others
10.5.8 Historic and Forecasted Market Size By Distribution Channel
10.5.8.1 Hospital Pharmacy
10.5.8.2 Retail Pharmacy
10.5.8.3 Others
10.5.9 Historic and Forecast Market Size by Country
10.5.9.1 China
10.5.9.2 India
10.5.9.3 Japan
10.5.9.4 South Korea
10.5.9.5 Malaysia
10.5.9.6 Thailand
10.5.9.7 Vietnam
10.5.9.8 The Philippines
10.5.9.9 Australia
10.5.9.10 New Zealand
10.5.9.11 Rest of APAC
10.6. Middle East & Africa Immune Checkpoint Inhibitors Market
10.6.1 Key Market Trends, Growth Factors and Opportunities
10.6.2 Top Key Companies
10.6.3 Historic and Forecasted Market Size by Segments
10.6.4 Historic and Forecasted Market Size By Indication
10.6.4.1 Breast Cancer
10.6.4.2 Bladder Cancer
10.6.4.3 Cervical Cancer
10.6.4.4 Hodgkin Lymphoma
10.6.4.5 Liver Cancer
10.6.4.6 Lung Cancer
10.6.4.7 Kidney Cancer
10.6.4.8 Solid Cancer
10.6.4.9 Others
10.6.5 Historic and Forecasted Market Size By Target
10.6.5.1 PD-1
10.6.5.2 PD-L1
10.6.5.3 CTLA-4
10.6.5.4 Others
10.6.6 Historic and Forecasted Market Size By Route of Administration
10.6.6.1 Oral
10.6.6.2 Parenteral
10.6.6.3 Others
10.6.7 Historic and Forecasted Market Size By End-Users
10.6.7.1 Hospitals
10.6.7.2 Specialty Clinics
10.6.7.3 Others
10.6.8 Historic and Forecasted Market Size By Distribution Channel
10.6.8.1 Hospital Pharmacy
10.6.8.2 Retail Pharmacy
10.6.8.3 Others
10.6.9 Historic and Forecast Market Size by Country
10.6.9.1 Turkiye
10.6.9.2 Bahrain
10.6.9.3 Kuwait
10.6.9.4 Saudi Arabia
10.6.9.5 Qatar
10.6.9.6 UAE
10.6.9.7 Israel
10.6.9.8 South Africa
10.7. South America Immune Checkpoint Inhibitors Market
10.7.1 Key Market Trends, Growth Factors and Opportunities
10.7.2 Top Key Companies
10.7.3 Historic and Forecasted Market Size by Segments
10.7.4 Historic and Forecasted Market Size By Indication
10.7.4.1 Breast Cancer
10.7.4.2 Bladder Cancer
10.7.4.3 Cervical Cancer
10.7.4.4 Hodgkin Lymphoma
10.7.4.5 Liver Cancer
10.7.4.6 Lung Cancer
10.7.4.7 Kidney Cancer
10.7.4.8 Solid Cancer
10.7.4.9 Others
10.7.5 Historic and Forecasted Market Size By Target
10.7.5.1 PD-1
10.7.5.2 PD-L1
10.7.5.3 CTLA-4
10.7.5.4 Others
10.7.6 Historic and Forecasted Market Size By Route of Administration
10.7.6.1 Oral
10.7.6.2 Parenteral
10.7.6.3 Others
10.7.7 Historic and Forecasted Market Size By End-Users
10.7.7.1 Hospitals
10.7.7.2 Specialty Clinics
10.7.7.3 Others
10.7.8 Historic and Forecasted Market Size By Distribution Channel
10.7.8.1 Hospital Pharmacy
10.7.8.2 Retail Pharmacy
10.7.8.3 Others
10.7.9 Historic and Forecast Market Size by Country
10.7.9.1 Brazil
10.7.9.2 Argentina
10.7.9.3 Rest of SA
Chapter 11 Analyst Viewpoint and Conclusion
11.1 Recommendations and Concluding Analysis
11.2 Potential Market Strategies
Chapter 12 Research Methodology
12.1 Research Process
12.2 Primary Research
12.3 Secondary Research
|
Global Immune Checkpoint Inhibitors Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 48.51 Billion |
|
Forecast Period 2024-32 CAGR: |
17.12% |
Market Size in 2032: |
USD 201.15 Billion |
|
Segments Covered: |
By Indication |
|
|
|
By Target |
|
||
|
By End-Users |
|
||
|
Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
